Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis

Kuderer, 2006, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, 106, 2258, 10.1002/cncr.21847 Link, 2001, Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care, Cancer, 92, 1354, 10.1002/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P Numnum, 2007, Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma: a cost-effectiveness analysis, Int. J. Gynecol. Cancer, 17, 1019, 10.1111/j.1525-1438.2007.00915.x Elder-Lissai, 2008, Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy, Value Health, 11, 172, 10.1111/j.1524-4733.2007.00242.x Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J. Clin. Oncol., 24, 3187, 10.1200/JCO.2006.06.4451 Crawford, 2007, Myeloid growth factors. Clinical practice guidelines in oncology, J. Natl. Compr. Cancer Netw., 5, 188, 10.6004/jnccn.2007.0019 Amgen: Neupogen prescribing information [internet]. Available from: pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf. Amgen: Neulasta prescribing information [internet]. Available from: 〈http://www.neulasta.com/pdf/Neulasta_PI.pdf〉. Holmes, 2006, Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer, J. Clin. Oncol., 20, 727, 10.1200/JCO.2002.20.3.727 Green, 2003, A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy, Ann. Oncol., 14, 29, 10.1093/annonc/mdg019 Pinto, 2007, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials, Curr. Med. Res. Opin., 23, 2283, 10.1185/030079907X219599 Siena, 2003, A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer, Oncol. Rep., 10, 715 Laskey, 2012, Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer, Gynecol. Oncol., 125, 625, 10.1016/j.ygyno.2012.03.015 Bookman, 2009, Evaluation of new platinum-based treatment regimens in advanced-staged ovarian cancer: a phase III trial of the Gynecologic, 27, 1419 Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, 365, 2473 Whitworth, 2009, The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies, Gynecol. Oncol., 112, 601, 10.1016/j.ygyno.2008.10.025 Lokich, 2006, Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma, Am. J. Clin. Oncol., 29, 361, 10.1097/01.coc.0000217816.16236.22 Saven, 2006, Randomized double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients, J. Clin. Oncol., 24 Belani, 2006, A randomized double-blind phase 2 study to evaluate same-day vs. next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC, J. Clin. Oncol., 24 Vance, 2006, Same-day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients, J. Clin. Oncol., 24 Schuman, 2009, Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer, J. Supp. Oncol., 7, 225 du Bois, 2003, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J. Natl. Cancer Inst., 95, 1320, 10.1093/jnci/djg036 Vasey, 2004, Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma, J. Natl. Cancer Inst., 96, 1682, 10.1093/jnci/djh323 Ozols, 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol., 21, 3194, 10.1200/JCO.2003.02.153 Neijt, 2000, Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J. Clin. Oncol., 18, 3084, 10.1200/JCO.2000.18.17.3084 Zamagni, 1998, The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I–II study, Am. J. Clin. Oncol., 21, 491, 10.1097/00000421-199810000-00015 Pfisterer, 2004, Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group, Gynecol. Oncol., 92, 949, 10.1016/j.ygyno.2003.12.004 Sharma, 2006, Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer, Gynecol. Oncol., 103, 181, 10.1016/j.ygyno.2006.02.012 Burris, 2010, Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: results of Four Multicenter, Double-Blind, Randomized Phase II Studies, J. Oncol. Pract., 6, 133, 10.1200/JOP.091094 Meehan, 2006, Resource utilization and time commitment associated with correction of anemia in cancer patients undergoing epoetin alfa, Clin. Drug Investig., 26, 593, 10.2165/00044011-200626100-00006 Fortner, 2004, Medical Visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities, BMC Cancer, 4, 22, 10.1186/1471-2407-4-22 Havrilesky, 2009, Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment, Gynecol. Oncol., 113, 216, 10.1016/j.ygyno.2008.12.026 N. Seer: Howlader, A. Noone, M. Krapcho, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute [internet]. Available from: 〈http://seer.cancer.gov/csr/1975_2009_pops09/〉. Patt, 2007, Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk, J. Clin. Oncol., 25, 3871, 10.1200/JCO.2007.12.0832 Hershman, 2007, Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant therapy, J. Natl. Cancer Inst., 99, 196, 10.1093/jnci/djk028